ADRA2A, adrenoceptor alpha 2A, 150

N. diseases: 102; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0424295
Disease: Hyperactive behavior
Hyperactive behavior
0.050 Biomarker phenotype BEFREE The selective α2A adrenoceptor agonist guanfacine reduces hyperactivity and improves cognitive impairment in patients with attention-deficit/hyperactivity disorder (ADHD). 30802458 2019
CUI: C0424295
Disease: Hyperactive behavior
Hyperactive behavior
0.050 GeneticVariation phenotype BEFREE Our data suggest that family environmental factors may act together with the alpha(2A)-adrenoceptor genotype to increase the expression of hyperactive and inattentive symptoms in adolescents. 19922756 2010
CUI: C0424295
Disease: Hyperactive behavior
Hyperactive behavior
0.050 GeneticVariation phenotype BEFREE Male ADRA2A -1291G allele homozygotes showed significant pretreatment HPA axis hyperactivity, with increased adrenocorticotropin (ACTH; F = 4.9, d.f. 19088492 2008
CUI: C0424295
Disease: Hyperactive behavior
Hyperactive behavior
0.050 GeneticVariation phenotype BEFREE The N251K polymorphism does not represent a genetic factor to explain the alpha(2A)-adrenoceptor hyperactivity in the brains of depressed suicide victims. 16333651 2006
CUI: C0424295
Disease: Hyperactive behavior
Hyperactive behavior
0.050 GeneticVariation phenotype BEFREE Although no association with either MspI allele was observed through the haplotype relative risk (HRR) analysis, effects of the ADRA2A gene on inattention and combined (inattention + hyperactivity/impulsivity) symptom scores were detected (U = 222.5, z = 2.19, P = 0.03; and U = 208.5, z = 2.32, P = 0.02, respectively). 12815749 2003